▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #433 by analyst upside · 2026-09-27
RCKT
Rocket Pharmaceuticals, Inc.
Healthcare · Market Cap $285M · P/E 0x
ANALYST PRICE TARGET
+241.2%
implied upside to consensus target
Current Price $2.6
Consensus Target $8.85
Bull Target $15.0
Bear Target $3.0
Analysts Covering 12
ANALYST CONSENSUS - HOLD
Strong Buy
1
Buy
5
Hold
4
Sell
2
52-Week Low $2.53
52-Week High $5.45
YTD Return -25.0%
FUNDAMENTALS
Market Cap $285M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.17
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $2.53
52-Week High $5.45
Current Price $2.6
Bear Target $3.0
Bull Target $15.0
● Now $2.6 ● Target $8.85
TRADING DATA
Avg Volume 1.7M
YTD Return -25.0%
Analyst Count 12
Consensus Hold
Upside to Target +241.2%
Last Updated 2026-09-27

ANALYST SUMMARY

Rocket Pharmaceuticals, Inc. (RCKT) is currently trading at $2.6 with a Wall Street consensus price target of $8.85, implying potential upside of 241.2% over the next 12 months. 12 analysts currently cover RCKT, with a consensus rating of Hold - 50% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $15.0, while the most cautious has a target of $3.0.

RCKT operates in the Healthcare sector with a market capitalisation of $285M. The stock is down 25.0% year-to-date and is currently trading near the lower end of its 52-week range of $2.53 – $5.45.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for RCKT, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Wedbush reit
Outperform → Outperform 2026-09-16 Building track record
Needham ↑ Upgrade
Hold → Buy 2026-09-16 20% win rate (5 calls)
Chardan Capital - Reiterated
Buy → Buy 2026-09-15 33% win rate (6 calls)
Chardan Capital - Reiterated
Buy → Buy 2026-09-01 33% win rate (6 calls)
Wedbush - Reiterated
Outperform → Outperform 2026-08-11 Building track record
Chardan Capital - Reiterated
Buy → Buy 2026-05-11 33% win rate (6 calls)
B of A Securities - Reiterated
Buy → Buy 2026-03-30 Building track record
Chardan Capital - Reiterated
Buy → Buy 2026-03-27 33% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
27
out of 100
Coverage depth
20/30
Consensus clarity
0/30
Vote unanimity
5/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →